Deutsche Bank AG Sells 11,578 Shares of Savara Inc. $SVRA

Deutsche Bank AG lowered its stake in Savara Inc. (NASDAQ:SVRA) by 1.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 916,017 shares of the company’s stock after selling 11,578 shares during the period. Deutsche Bank AG owned approximately 0.53% of Savara worth $2,537,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of SVRA. XTX Topco Ltd bought a new stake in shares of Savara in the 4th quarter worth approximately $34,000. Ameriprise Financial Inc. purchased a new position in shares of Savara during the fourth quarter valued at about $37,000. Hsbc Holdings PLC purchased a new position in shares of Savara during the fourth quarter valued at about $48,000. Jump Financial LLC bought a new position in shares of Savara in the 4th quarter valued at about $64,000. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of Savara in the 1st quarter valued at about $74,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Guggenheim reaffirmed a “buy” rating and set a $8.00 price target (down previously from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Evercore ISI lowered their price target on shares of Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a report on Wednesday, May 28th. HC Wainwright upgraded shares of Savara from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $2.00 to $5.00 in a research report on Friday, August 15th. Wells Fargo & Company reduced their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a research report on Wednesday, May 28th. Finally, Oppenheimer increased their price target on shares of Savara from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Friday, August 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and a consensus price target of $6.17.

Savara Price Performance

Shares of NASDAQ:SVRA opened at $3.05 on Wednesday. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. Savara Inc. has a fifty-two week low of $1.89 and a fifty-two week high of $4.70. The firm’s 50-day simple moving average is $2.42 and its 200-day simple moving average is $2.66. The company has a market cap of $527.16 million, a price-to-earnings ratio of -6.10 and a beta of 0.40.

Savara (NASDAQ:SVRA) last announced its earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.02). As a group, equities research analysts predict that Savara Inc. will post -0.45 earnings per share for the current year.

Insider Transactions at Savara

In other news, Director Richard J. Hawkins bought 48,225 shares of the firm’s stock in a transaction dated Friday, June 20th. The stock was acquired at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the completion of the purchase, the director owned 115,466 shares of the company’s stock, valued at $235,550.64. This trade represents a 71.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.13% of the stock is currently owned by corporate insiders.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.